Review of treatment options for oligometastatic non-small cell lung cancer.
Our understanding of metastatic disease is constantly evolving. Although outcomes for patients with stage IV non-small cell lung cancer (NSCLC) are poor, aggressive/radical local intervention may be effective in a subset of patients with limited or "oligometastatic" disease. Here we review and compare the range of available treatment options that are specific to oligometastatic NSCLC, and discuss potential directions of future clinical research.
University of Texas Southwest Medical Center, Dallas, Texas.
Michael R
MR
Folkert
University of Texas Southwest Medical Center, Dallas, Texas.
Robert
R
Timmerman
D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D003131:Combined Modality Therapy / Q000009:adverse effects / Q000379:methods; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D016896:Treatment Outcome